Article
Radiology, Nuclear Medicine & Medical Imaging
Philip McGeachy, Elizabeth Watt, Siraj Husain, Kevin Martell, Pedro Martinez, Summit Sawhney, Kundan Thind
Summary: This study investigated the accuracy of MIM algorithms for MRI-TRUS fusion, showing that the CB deformable registration algorithm yielded the best geometric registration indices. MIM offers a commercial platform that allows for easier access and integration into clinical departments, with potential to play a key role in future focal therapy applications for prostate cancer.
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
(2021)
Article
Oncology
Peter Hass, Frank Fischbach, Maciej Pech, Ahmed Gawish
Summary: This study evaluated the oncologic, functional, and toxicological results of mid-term F-BT therapy in patients with low to intermediate-risk prostate cancer. The results showed that F-BT is a safe and effective treatment for selected patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Isabel E. Jimenez-Garcia, Sebastia Sabater, Rocio Martinez-Gutierrez, Pedro Sanchez-Galiano, Roberto Berenguer-Serrano, Susana Castro-Larefors, Irene Rey-Lopez, Beatriz Ruiz-Herrero, Ricardo Sanchez-Prieto, Angeles Rovirosa, Meritxell Arenas, Herminio A. Gonzalez-Suarez
Summary: This study compared the clinical outcomes of high-dose-rate (HDR) and low-dose-rate (LDR) brachytherapy for primary prostate cancer, and found that LDR brachytherapy had better biochemical relapse-free survival and overall survival rates compared to HDR brachytherapy.
Article
Oncology
Marnix J. A. Rasing, Max Peters, Marieke van Son, Marinus A. Moerland, Wietse Eppinga, Sandrine M. G. van de Pol, Juus Noteboom, Jan Lagendijk, Jochem R. N. van der Voort vanZyp
Summary: The purpose of this study was to investigate the recurrence characteristics in patients treated with focal salvage HDR brachytherapy. The results showed that after 19 Gy HDR brachytherapy, subsequent recurrences were mainly local and in-field.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Rohann J. M. Correa, Gerard Morton, Hans T. Chung, Chia-Lin Tseng, Patrick Cheung, William Chu, Stanley K. Liu, Merrylee McGuffin, Anam Shahid, Melanie Davidson, Ananth Ravi, Joelle Helou, Yasir Alayed, Liying Zhang, Alexandre Mamedov, Andrew Loblaw
Summary: This study compared the outcomes of two-fraction prostate SABR and two-fraction HDR monotherapy. The results showed similar rates of biochemical failure, toxicity, and quality of life between the two treatment approaches. These findings support the need for a randomized controlled trial to further evaluate these treatments.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
Jean -Michel Hannoun-Levi, Marie-Eve Chand-Fouche, Tanguy Pace-Loscos, Mathieu Gautier, Jocelyn Gal, Renaud Schiappa, Nina Pujol
Summary: The long-term results of the SiFEPI trial show that a single fraction of 20 Gy leads to sub-optimal biochemical control for low-risk and favorable-intermediate-risk prostate cancers. The late genito-urinary and gastrointestinal toxicity profiles are encouraging, suggesting that HDB may be a safe irradiation technique.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2022)
Article
Oncology
G. Nagore, E. Moreno-Olmedo, V. Suarez-Gironzini, L. Aakki, Ramos-Garcia LI, E. Gomez, A. Garcia, L. Beltran, A. Gomez-Iturriaga
Summary: In this prospective cohort study, we demonstrate the long-term cancer control results of two fractions HDR-BRT administered in a single day and investigate the relationship between PSA nadir and biochemical control. Our findings show that HDR-BT monotherapy is highly effective in achieving curative outcomes for patients with favorable localized prostate cancer.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Yasir Alayed, Andrew Loblaw, Merrylee McGuffin, Hans T. Chung, Chia-Lin Tseng, Laura D'Alimonte, Patrick Cheung, Stanley Liu, William Chu, Ewa Szumacher, Joelle Helou, Ananth Ravi, Masoom Haider, Alexandre Mamedov, Liying Zhang, Gerard Morton
Summary: MRI-guided focal boost did not significantly improve local control for localized prostate cancer treated with single-fraction HDR monotherapy. Dosimetric parameters were not significant predictors of biochemical failure. Single-fraction HDR monotherapy should not be recommended outside of clinical trials.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Thomas Reynaud, Lara Hathout, Damien Carignan, Maroie Barkati, Andre-Guy Martin, William Foster, Frederic Lacroix, Guila Delouya, Daniel Taussky, Gerard Morton, Eric Vigneault
Summary: This study evaluated the PSA outcomes, HRQOL, and toxicity of single-fraction High-Dose-Rate brachytherapy (HDRB) and Low-Dose-Rate brachytherapy (LDRB) for prostate cancer patients. The results showed that HDRB resulted in superior HRQOL in the irritative urinary domain compared to LDRB, while the LDRB group had significantly lower PSA nadir and a higher proportion of patients reaching PSA < 0.4 ng/mL.
Article
Engineering, Biomedical
Marjolein C. van der Meer, Peter A. N. Bosman, Yury Niatsetski, Tanja Alderliesten, Bradley R. Pieters, Arjan Bel
Summary: The study introduced a bi-objective optimization approach for HDR prostate brachytherapy plans, incorporating dose-volume indices. By examining different reconstruction settings, a robust optimization model was developed to address differences in 3D organ shape. Results showed that robust optimization improved plan quality without significantly increasing runtime.
PHYSICS IN MEDICINE AND BIOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Catherine Holly Frank, Pavitra Ramesh, Qihui Lyu, Dan Ruan, Sang-June Park, Albert J. Chang, Puja S. Venkat, Amar U. Kishan, Ke Sheng
Summary: This study presents a novel analytical approach to solving the HDR planning problem by integrating catheter and isotope selection with dwell time optimization. The proposed method can guide HDR implants and identify promising isotopes for specific clinical goals.
Article
Radiology, Nuclear Medicine & Medical Imaging
Stefan Gerlach, Frank-Andre Siebert, Alexander Schlaefer
Summary: The purpose of this study is to efficiently address uncertainty during inverse planning for HDR BT in order to robustly optimize the pose of the needles before insertion, that is, to facilitate path planning for robotic needle placement.
Article
Oncology
Hima Bindu Musunuru, Patrick Cheung, Danny Vesprini, Stanley K. Liu, William Chu, Hans T. Chung, Gerard Morton, Andrea Deabreu, Melanie Davidson, Ananth Ravi, Joelle Helou, Ling Ho, Liying Zhang, Andrew Loblaw
Summary: Guidelines recommend brachytherapy boost for intermediate or high-risk prostate cancer patients. A study compared efficacy, toxic effects, and QoL in patients treated with SABR boost or HDR-BT boost with ADT. Results showed no significant difference in toxicity or QoL between the two treatments, with efficacy favoring SABR boost.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
David Grajales, Samuel Kadoury, Roozbeh Shams, Maroie Barkati, Guila Delouya, Dominic Beliveau-Nadeau, Benedicte Nicolas, William Trung Le, Mustafa-Karim Benhacene-Boudam, Daniel Juneau, Jean N. DaSilva, Jean-Francois Carrier, Gilion Hautvast, Cynthia Menard
Summary: This study reports on the accuracy and workflow performance of a prototype system in supporting tumor-targeted procedures. The system integrates multimodal image registration and electromagnetic tracking technologies, improving accuracy in navigation and targeting while allowing the use of partially visible catheters. However, image registration errors should be carefully considered.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yizheng Chen, Lei Xing, Lequan Yu, Wu Liu, Benjamin Pooya Fahimian, Thomas Niedermayr, Hilary P. Bagshaw, Mark Buyyounouski, Bin Han
Summary: A novel segmentation-based registration framework was proposed in this study to automatically register prostate MR images to treatment planning US images with metal artifacts, saving labor work and improving accuracy. The evaluation results demonstrate the potential of this approach in HDR prostate brachytherapy practice.